| | |
Total
|
Goup 1
|
Group 2
|
P value
|
|---|
|
Subjects (n)
| |
14
|
7
|
7
| |
|
Sex (M/F)
| |
3/11
|
2/5
|
1/6
|
NS
|
|
Age (mean ± SD)
| |
56.00 ± 12.94
|
61.30 ± 6.47
|
50.71 ± 16.00
|
NS
|
|
HCV genotype
|
1b
|
11 (78.57%)
|
6 (85.71%)
|
5 (71.43%)
|
NS
|
| |
2a
|
2 (14.29%)
|
1 (14.29%)
|
1 (14.29%)
|
NS
|
| |
ND (serotype 2)
|
1 (7.14%)
|
0 (0%)
|
1 (14.29%)
|
NS
|
|
HCV RNA level
|
High
|
12 (85.71%)
|
6 (85.71%)
|
6 (85.71%)
|
NS
|
| |
Low
|
2 (14.29%)
|
1 (14.29%)
|
1 (14.29%)
|
NS
|
|
Weight loss during IFN therapy
| |
5.69 ± 4.57
|
8.71 ± 2.81
|
2.66 ± 4.00
|
0.0088
|
|
Neutrophil count (μ/L)
|
Before IFN
|
2546.11 ± 793.47
|
2481.34 ± 599.67
|
2610.89 ± 997.36
|
NS
|
| |
2 weeks after IFN
|
1229.11 ± 590.25
|
1260.51 ± 473.58
|
1197.70 ± 726.82
|
NS
|
| |
3 months after IFN
|
1343.05 ± 584.48
|
1636.51 ± 670.69
|
1049.59 ± 298.98
|
NS
|
| |
6 months after IFN
|
1319.11 ± 301.15
|
1442.69 ± 194.15
|
1195.53 ± 350.95
|
NS
|
| |
End of treatment
|
1360.21 ± 547.74
|
1420.54 ± 401.41
|
1299.87 ± 693.13
|
NS
|
| |
6 months after treatment
|
2349.21 ± 695.36
|
2578.63 ± 716.47
|
2119.80 ± 641.48
|
NS
|
|
PLT (x10-4/μL)
|
Before IFN
|
17.58 ± 7.06
|
17.54 ± 3.32
|
17.61 ± 9.84
|
NS
|
| |
2 weeks after IFN
|
14.04 ± 7.28
|
14.37 ±4.70
|
13.71 ± 9.61
|
NS
|
| |
3 months after IFN
|
13.69 ± 6.08
|
14.27 ± 5.36
|
13.11 ± 7.12
|
NS
|
| |
6 months after IFN
|
13.20 ± 5.31
|
14.21 ± 4.72
|
12.19 ± 6.03
|
NS
|
| |
End of treatment
|
14.45 ± 5.05
|
14.50 ± 4.59
|
14.40 ± 5.84
|
NS
|
| |
6 months after treatment
|
16.86 ± 6.03
|
18.14 ± 4.29
|
15.59 ± 7.52
|
NS
|
|
Hb (g/dL)
|
Before IFN
|
13.97 ±1.08
|
13.91 ±1.26
|
14.03 ± 0.97
|
NS
|
| |
2 weeks after IFN
|
13.04 ±1.06
|
13.33± 1.34
|
12.76 ± 0.67
|
NS
|
| |
3 months after IFN
|
10.94 ±1.55
|
10.40 ±1.57
|
11.47 ±1.45
|
NS
|
| |
6 months after IFN
|
10.61 ±1.73
|
9.81 ± 1.45
|
11.41 ± 1.70
|
NS
|
| |
End of treatment
|
10.99 ±1.74
|
10.23 ± 1.89
|
11.74 ± 1.27
|
NS
|
| |
6 months after treatment
|
13.29 ±1.48
|
12.99 ± 2.05
|
13.59 ± 0.58
|
NS
|
|
Alb (g/dL)
|
Before IFN
|
4.18 ± 0.35
|
4.10 ± 0.34
|
4.26 ± 0.36
|
NS
|
| |
2 weeks after IFN
|
3.76 ± 0.48
|
3.75 ± 0.38
|
3.76 ± 0.59
|
NS
|
| |
3 months after IFN
|
3.84 ± 0.37
|
3.76 ± 0.45
|
3.92 ± 0.28
|
NS
|
| |
6 months after IFN
|
3.88 ± 0.33
|
3.74 ± 0.42
|
4.02 ± 0.12
|
0.0550
|
| |
End of treatment
|
3.90 ± 0.38
|
3.77 ± 0.35
|
4.03 ± 0.39
|
NS
|
| |
6 months after treatment
|
4.27 ± 0.35
|
4.23 ± 0.34
|
4.30 ± 0.39
|
NS
|
|
Salivary flow (g/2 min)
|
Before IFN
|
6.10 ± 1.81
|
5.86 ± 1.90
|
6.38 ± 1.81
|
NS
|
| |
2 weeks after IFN
|
5.71 ± 2.60
|
5.88 ± 2.33
|
5.55 ± 3.03
|
NS
|
| |
3 months after IFN
|
5.23 ± 2.14
|
4.92 ± 2.34
|
5.53 ± 2.06
|
NS
|
| |
6 months after IFN
|
5.42 ± 1.97
|
5.32 ± 2.14
|
5.51 ± 1.94
|
NS
|
| |
End of treatment
|
5.31 ± 2.06
|
5.33 ± 1.58
|
5.30 ± 2.58
|
NS
|
| |
6 months end of IFN
|
6.02 ± 1.81
|
6.03 ± 1.38
|
6.00 ± 2.28
|
NS
|
|
Diabetes mellitus
|
positive, n (%)
|
2 (14.29%)
|
1 (14.29%)
|
1 (14.29%)
|
NS
|
|
Oral mucosal lesions
|
positive, n (%)
|
7 (50.00%)
|
6 (85.71%)
|
1 (14.29%)
|
0.0075
|
|
Steroid for external use
|
positive, n (%)
|
6 (42.86%)
|
5 (71.43%)
|
1 (14.29%)
|
0.0308
|
|
Tooth-brushing after every meal
|
yes, n (%)
|
8 (57.14%)
|
3 (42.86%)
|
5 (71.43%)
|
NS
|
|
Denture wearer
|
yes, n (%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
NS
|
|
Administration of antifungal agent
|
yes, n (%)
|
2 (14.29%)
|
2 (28.57%)
|
0 (0%)
|
NS
|
|
Effect of IFN therapy
|
SVR , n (%)
|
11 (78.57%)
|
6 (85.71%)
|
5 (71.43%)
|
NS
|
- HCV, hepatitis C virus; IFN, interferon; M, male; F, female; ND, not detected; NS, not significant; PLT, platelets; Hb, hemoglobin; Alb, albumin.
